Forum for Applied Imaging Research (FAIR): Multidisciplinary Imaging and Treatment of Neuroendocrine Tumors (NETs)
Date
Type
Time Duration
Location
Speakers
Director, Center for Neuroendocrine Tumors
Introduction to Neuroendocrine Tumors (NET) and Current Unsolved Problems
Dr. Bergsland is an internationally recognized medical oncologist with expertise in neuroendocrine tumors. She is a Professor of Clinical Medicine, and Ernest Rosenbaum Endowed Chair in Medical Oncology at UCSF. She also serves as the Associate Director for Education at the Helen Diller Family Comprehensive Cancer Center.
Nationally, she is co-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, a member of the NCCN Neuroendocrine Tumors Guidelines Panel, a member of the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS), and co-chair of the 8th edition AJCC Expert Panel on staging for NETs.
Her research efforts are focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs).
Assistant Director, Nuclear Medicine Residency and Fellowship Programs
University of California San Francisco
Current and Future Radionuclide Therapies for NET
Dr. Lawhn Heath is an Assistant Professor of Molecular Imaging and Therapeutics in the Department of Radiology and Biomedical Imaging at the University of California San Francisco (UCSF), where she also serves as Associate Program Director of the UCSF Molecular Imaging and Therapeutics fellowship programs. Recently, she was elected to the Board of Directors of the Society of Nuclear Medicine and Molecular Imaging’s PET Center of Excellence and appointed Chair of the SNMMI Clinical Trials Network’s Education Committee.
Dr. Lawhn Heath was awarded the 2020 Rahul Desikan Award for Outstanding Research by a Junior Faculty or Fellow by the UCSF Department of Radiology and Biomedical Imaging. Her research interests include somatostatin receptor PET, targeted radionuclide therapy, and the molecular imaging of breast and prostate cancer.
Director, Interventional Oncology
Current and Future Liver Directed Therapy for NET
Dr. Nicholas Fidelman is a Professor of Radiology and Biomedical Imaging at the University of California San Francisco (UCSF). Dr. Fidelman obtained his M.D. degree at UCSF in 2002, completed his residency in Diagnostic Radiology in 2007, and fellowship in Vascular and Interventional Radiology at UCSF in 2008. Dr. Fidelman’s clinical and research interests are in the area of liver oncology and biliary interventions.
NET: a Patient's Perspective
Josh Mailman is an internationally recognized advocate for neuroendocrine tumor patients as well as an advocate for integrative oncology, nuclear medicine, and molecular imaging. Josh is currently the sole patient representative to the US Nuclear Regulatory Commission's Advisory Board on the Medical Use of Isotopes, he co-chairs the National Cancer Institute’s Patient Advocate Steering Committee and is a member of ASCO’s Scientific Committee in addition to being a member of the INCA Research Committee.
Josh is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of the Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and President of the NorCal CarciNET Community. He has an MBA from the Anderson School of Management at UCLA and has been a technology entrepreneur for more than 20 years.